Pegylated IFN- alpha 2b + Ribavirin

ApprovedCompleted
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Hepatitis C

Conditions

Hepatitis C

Trial Timeline

Apr 1, 2002 → Apr 1, 2007

About Pegylated IFN- alpha 2b + Ribavirin

Pegylated IFN- alpha 2b + Ribavirin is a approved stage product being developed by Tempus AI for Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT00277862. Target conditions include Hepatitis C.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C were approved

Approved (20) Terminated (8) Active (0)

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00277862ApprovedCompleted

Competing Products

20 competing products in Hepatitis C

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
43
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
40
SOF + COPEChugai PharmaceuticalPre-clinical
26
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
FK788Astellas PharmaPhase 2
35
MK-2248MerckPhase 1
29
Interferon alfacon-1Astellas PharmaPhase 3
40
Pegylated Interferon + RibavirinAstellas PharmaApproved
35
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir + MethadoneShionogiPhase 1
29
Clevudine + AdefovirEisaiPhase 3
40